Dirk Lange is the Head of Life Science Services at the Life Science business of Merck KGaA, Darmstadt, Germany (and/or its affiliates), as of February 15, 2022. In this role, he oversees the fully integrated contract development manufacturing organization (CDMO) and contract testing services for the Life Science business, including traditional modalities such as monoclonal antibodies (mAbs) and high-potency active pharmaceutical ingredients (HPAPIs), and novel modalities such as antibody–drug conjugates (ADCs) and viral and gene therapies (VGTs), as well as the businesses’ mRNA offering. Lange brings over two decades of experience in life science client services organizations and an extensive background in clinical and commercial operations across multiple modalities, quality remediation, supply chain, and third-party operations. Before joining MilliporeSigma, Lange was President and CEO of U.S.-based KBI Biopharma, a CDMO providing integrated drug development and biomanufacturing services, and CEO of Selexis SA, a cell line development company. Before returning to the U.S. in 2016, Lange held leadership positions in biopharmaceutical companies throughout Europe, including Novartis Biologics, Sandoz Oncology Injectables, and Rentschler Biopharma. Lange received his Master Professional (CCI) of Technical Management and his Bachelor Professional (CCI) of Pharmaceutical Technology. He also taught economics and operations management at the Chamber of Commerce and Industry in Ulm, Germany.